Elicit: Total Analytical Error in Liver Fibrosis Panels (public)
For a liver fibrosis panel, what is total analytical error by population (NAFLD, viral hepatitis, alcohol-related)?
Total analytical error was not explicitly reported for liver fibrosis panels in any population (NAFLD, viral hepatitis, alcohol-related), with studies instead using sensitivity, specificity, and AUROC metrics.
Abstract
No study reported an explicit total analytical error for liver fibrosis panels. Instead, papers quantified diagnostic performance using metrics such as sensitivity, specificity, AUROC, and predictive values. In nonalcoholic fatty liver disease (NAFLD), panels based on FIB-4, NAFLD Fibrosis Score, and APRI showed:
- Sensitivity ranging from 7% to 33% in general NAFLD (with negative predictive values of 98–99% when compared to transient elastography)
- In patients with Type 2 Diabetes Mellitus, FIB-4 reached sensitivities of 81.6–95.9% and AUROC values of 0.79–0.91
- In NAFLD/NASH studies incorporating novel markers (e.g., RAB14, PLIN2), sensitivities of 88–100%, specificities of 89.6–100%, and AUROC up to 0.99 were noted
In viral hepatitis, panels including Hepascore, FIB-4, APRI, and FIBROSpect II demonstrated sensitivities between 71.8% and 82%, specificities around 65–74%, and AUROC values of 0.81–0.83. For alcohol-related liver disease, tests such as Enhanced Liver Fibrosis and FibroTest yielded AUROC figures of 0.90–0.92 with negative predictive values of 97–98%, along with false positive rates of 8–45% and false negatives below 8%.
Methods
We analyzed 40 sources from an initial pool of 996, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.
Papers identified with Elicit search
- n = 996
Papers screened using:
Fibrosis Panel Assessment
Analytical Error Reporting
Target Population
Reference Standard
Study Type and Setting
Adult Population
Publication Type
Outcome Measures
n = 996 papers screened out
Papers included for extraction
- n = 40
Characteristics of Included Studies
Study Population and Setting
- Total number of participants: Various studies present different populations.
- Population type: NAFLD, viral hepatitis, alcohol-related liver disease.
Liver Fibrosis Assessment Method
- Primary method of fibrosis assessment: Various methodologies including liver biopsy, transient elastography, and non-invasive scoring systems.
Total Analytical Error Measurements
Quantitative data collected includes:
- Analytical error rates
- Sensitivity
- Specificity
- AUROC values
Variability and Measurement Precision
Information on:
- Intra-individual variability and measurement error sources is extracted from study discussions.
Study Limitations and Bias Considerations
Potential sources of bias and limitations identified through author's discussions.
Results
Total Analytical Error by Population
| Population | Fibrosis Test | Total Analytical Error | Reference Standard |
|---|---|---|---|
| NAFLD (general) | FIB-4, NFS, APRI | Sensitivity 7–33%, Specificity 87–100% | Transient Elastography |
| NAFLD (Type 2 Diabetes Mellitus) | FIB-4 | Sensitivity 81.6–95.9%, AUROC 0.79–0.91 | Magnetic Resonance Elastography, biopsy |
| HCV | Hepascore, FIB-4, APRI | Sensitivity 82%, Specificity 65%, AUROC 0.81–0.83 | Biopsy |
Summary
- Across included studies, total analytical error for liver fibrosis panels is not explicitly reported.
- Performance metrics such as sensitivity, specificity, and AUROC are available and indicate the reliability of various tests for diagnosing liver fibrosis.
- Population-specific factors and test-specific limitations must be considered when interpreting results.